Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | 0.17 | -0.02 | 0.61 |
| FCF Yield | 10.63% | -8.22% | -28.69% | 1.16% |
| EV / EBITDA | 10.48 | -16.50 | -5.12 | -41.06 |
| Quality | ||||
| ROIC | 21.22% | -28.24% | -77.87% | -7.52% |
| Gross Margin | 89.60% | 93.92% | 98.55% | 99.27% |
| Cash Conversion Ratio | 1.80 | 0.23 | 1.26 | -0.33 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.24% | -7.82% | 3.45% | 36.03% |
| Free Cash Flow Growth | 251.55% | 72.05% | -1,513.22% | 109.82% |
| Safety | ||||
| Net Debt / EBITDA | 0.11 | -1.64 | -0.32 | -1.03 |
| Interest Coverage | 3.06 | -2.98 | -14.99 | -1.85 |
| Efficiency | ||||
| Inventory Turnover | 3.11 | 1.29 | 0.19 | 0.16 |
| Cash Conversion Cycle | 136.85 | 12.24 | -2,671.98 | 988.59 |